163 related articles for article (PubMed ID: 38378457)
1. Exploring the therapeutic potential of isoorientin in the treatment of osteoporosis: a study using network pharmacology and experimental validation.
Zhang B; Qu Z; Hui H; He B; Wang D; Zhang Y; Zhao Y; Zhang J; Yan L
Mol Med; 2024 Feb; 30(1):27. PubMed ID: 38378457
[TBL] [Abstract][Full Text] [Related]
2. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.
Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q
Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.
Hyeon S; Lee H; Yang Y; Jeong W
Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472
[TBL] [Abstract][Full Text] [Related]
5. Treatment with hydrogen molecules prevents RANKL-induced osteoclast differentiation associated with inhibition of ROS formation and inactivation of MAPK, AKT and NF-kappa B pathways in murine RAW264.7 cells.
Li DZ; Zhang QX; Dong XX; Li HD; Ma X
J Bone Miner Metab; 2014 Sep; 32(5):494-504. PubMed ID: 24196871
[TBL] [Abstract][Full Text] [Related]
6. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
7. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
8. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
9. Urolithin B suppresses osteoclastogenesis via inhibiting RANKL-induced signalling pathways and attenuating ROS activities.
Qu Z; An H; Feng M; Huang W; Wang D; Zhang Z; Yan L
J Cell Mol Med; 2022 Aug; 26(16):4428-4439. PubMed ID: 35781786
[TBL] [Abstract][Full Text] [Related]
10. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.
Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H
Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839
[TBL] [Abstract][Full Text] [Related]
11. Thiaplakortone B attenuates RANKL-induced NF-κB and MAPK signaling and dampens OVX-induced bone loss in mice.
Wang Q; Chen D; Wang Y; Dong C; Liu J; Chen K; Song F; Wang C; Yuan J; Davis RA; Kuek V; Jin H; Xu J
Biomed Pharmacother; 2022 Oct; 154():113622. PubMed ID: 36081291
[TBL] [Abstract][Full Text] [Related]
12. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
[TBL] [Abstract][Full Text] [Related]
13. Isorhamnetin attenuates osteoarthritis by inhibiting osteoclastogenesis and protecting chondrocytes through modulating reactive oxygen species homeostasis.
Zhou F; Mei J; Yuan K; Han X; Qiao H; Tang T
J Cell Mol Med; 2019 Jun; 23(6):4395-4407. PubMed ID: 30983153
[TBL] [Abstract][Full Text] [Related]
14. Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species.
Chen K; Qiu P; Yuan Y; Zheng L; He J; Wang C; Guo Q; Kenny J; Liu Q; Zhao J; Chen J; Tickner J; Fan S; Lin X; Xu J
Theranostics; 2019; 9(6):1634-1650. PubMed ID: 31037128
[No Abstract] [Full Text] [Related]
15. Icariin ameliorates osteoporosis in ovariectomized rats by targeting Cullin 3/Nrf2/OH pathway for osteoclast inhibition.
Si Y; Li Y; Gu K; Yin H; Ma Y
Biomed Pharmacother; 2024 Apr; 173():116422. PubMed ID: 38471268
[TBL] [Abstract][Full Text] [Related]
16. Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis.
Ye X; Jiang J; Yang J; Yan W; Jiang L; Chen Y
Acta Biochim Biophys Sin (Shanghai); 2022 Aug; 54(8):1080-1089. PubMed ID: 35929595
[TBL] [Abstract][Full Text] [Related]
17. Isoimperatorin attenuates bone loss by inhibiting the binding of RANKL to RANK.
Li H; Deng W; Qin Q; Lin Y; Liu T; Mo G; Shao Y; Tang Y; Yuan K; Xu L; Li Y; Zhang S
Biochem Pharmacol; 2023 May; 211():115502. PubMed ID: 36921635
[TBL] [Abstract][Full Text] [Related]
18. Cichoric acid targets RANKL to inhibit osteoclastogenesis and prevent ovariectomy-induced bone loss.
Xian Y; Gao Y; Su Y; Su Y; Lian H; Feng X; Liu Z; Zhao J; Xu J; Liu Q; Song F
Phytother Res; 2024 Apr; 38(4):1971-1989. PubMed ID: 38358727
[TBL] [Abstract][Full Text] [Related]
19. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
[No Abstract] [Full Text] [Related]
20. Hesperetin suppresses RANKL-induced osteoclastogenesis and ameliorates lipopolysaccharide-induced bone loss.
Liu H; Dong Y; Gao Y; Zhao L; Cai C; Qi D; Zhu M; Zhao L; Liu C; Guo F; Xiao J; Huang H
J Cell Physiol; 2019 Jul; 234(7):11009-11022. PubMed ID: 30548260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
